Chiral Technologies

Executive Summary

Chiral Technologies, a Daicel company, is a leading provider of optical isomer separation solutions for the pharmaceutical industry and academic research. Established in 1990 and headquartered in West Chester, USA, the company specializes in chiral chromatography and related technologies essential for producing enantiomerically pure drug compounds. With decades of expertise and a reputation for reliability, Chiral Technologies serves as a critical partner in drug development, enabling the isolation of single enantiomers that are often required for safety and efficacy. As regulatory scrutiny on chiral purity intensifies and the demand for new chiral drugs grows, the company is well-positioned to benefit from its established customer base and continuous innovation in separation technologies. While privately held, its strategic importance in the pharmaceutical supply chain suggests steady demand and potential for expansion into adjacent markets.

Upcoming Catalysts (preview)

• Q3 2026Launch of new chiral stationary phase columns with enhanced throughput75% success
• Q4 2026Strategic partnership with a major pharmaceutical company for chiral method development60% success
• TBDPublication of new FDA guidance emphasizing continuous manufacturing for chiral drugs50% success